GALD.SW GALDERMA GROUP N | CH1335392721
Company Profile
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Latest News
Dow Jones Futures Rise, Oil Prices Dive On Iran Hopes; Apple Leads Earnings Wave, Fed Meeting Ahead
Investor's Business Daily • 07/27/2026
Aktsiaselts Infortar own share acquisition transactions
GlobeNewswire • 07/27/2026
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
GlobeNewswire • 07/27/2026
India Electrical Switches Market to Reach USD 1,864.83 Million by 2032 - Credence Research
PR Newswire • 07/27/2026
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.galderma.com |
| Audit Risk | 8 |
| Board Risk | 3 |
| Overall Risk | 5 |
| Market Cap | 40.49B |
| Trailing P/E | 58.47 |
| Forward P/E | 31.97 |
| Dividend Rate | 0.35 |
| Dividend Yield | 0.20% |
| Trailing Annual Div. Rate | 0.44 |
| Trailing Annual Div. Yield | 0.26% |
| Trailing EPS | 2.97 |
| Forward EPS | 5.43 |
| Book Value | 28.43 |
| Price-to-Book | 6.11 |
| Enterprise-to-Revenue | 8.15 |
| Enterprise-to-EBITDA | 37.66 |
| Ex-Dividend Date | 04/24/2026 |
| Dividend Date | 04/29/2025 |
| Earnings Date | |
| Earnings Call Date | 07/23/2026 |
| Revenue Average | 1.57B |
| Revenue Low | 1.57B |
| Revenue High | 1.57B |